Toggle Dropdown
Announcements
Projects
Welcome guest
Log in
Loading
Loading...
https://www.marketwatch.com/story/sage-therapeutics-stock-craters-49-after-fda-approves-zuranolone-for-postpartum-depression-but-not-major-depressive-disorder-2648cefa
0
0
Sage Therapeutics’ stock craters 49% after FDA approves zuranolone for postpartum depression, but not major depressive disorder - MarketWatch
8/7/23 at 5:01am
Organization
MarketWatch
Author
Ciara Linnane
Details
33 words
Summarize
Business & Industrial
Mental Health
FDA
Sage Therapeutics
Oppenheimer
MarketWatch
Wedbush
Oppenheimer and Wedbush downgraded Sage’s stock and said they were disappointed by the news
Show more
Create an account
or
login
to join the discussion
Modal title
...
Profile
Loading profile
Loading...